Established and emerging concepts to treat imbalances of iron homeostasis in inflammatory diseases

Pharmaceuticals

Volumn 11, Issue 4, 2018, Pages

  Petzer, Verena ^a   Theurl, Igor ^a   Weiss, Günter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anemia of chronic disease; Anemia of inflammation; Anti hepcidin therapy; Hepcidin; Iron supplementation

Indexed keywords

ADALIMUMAB; ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 6; C REACTIVE PROTEIN; CSJ 137; ERYTHROPOIETIN; FERRITIN; GOLIMUMAB; HEPCIDIN; INFLIXIMAB; INTERLEUKIN 6; IRON; MOMELOTINIB; PRS 080; RONEPARSTAT; SILTUXIMAB; SPIEGELMER; TOCILIZUMAB; TP 0184; TRANSFERRIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ENZYME METABOLISM; ERYTHROCYTE; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATORY DISEASE; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON THERAPY; MEAN CORPUSCULAR VOLUME; NONHUMAN; REVIEW; TRANSFERRIN BLOOD LEVEL;

EID: 85067048634     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/PH11040135     Document Type: Review

References (204)

1. Muckenthaler, M.U.; Rivella, S.; Hentze, M.W.; Galy, B. A Red Carpet for Iron Metabolism. Cell 2017, 168, 344-361.
2. Nemeth, E.; Rivera, S.; Gabayan, V.; Keller, C.; Taudorf, S.; Pedersen, B.K.; Ganz, T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 2004, 113, 1271-1276.
3. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090-2093.
4. Donovan, A.; Brownlie, A.; Zhou, Y.; Shepard, J.; Pratt, S.J.; Moynihan, J.; Paw, B.H.; Drejer, A.; Barut, B.; Zapata, A.; et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000, 403, 776-781.
5. Donovan, A.; Lima, C.A.; Pinkus, J.L.; Pinkus, G.S.; Zon, L.I.; Robine, S.; Andrews, N.C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005, 1, 191-200.
6. Nicolas, G.; Chauvet, C.; Viatte, L.; Danan, J.L.; Bigard, X.; Devaux, I.; Beaumont, C.; Kahn, A.; Vaulont, S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Investig. 2002, 110, 1037-1044.
7. Verga Falzacappa, M.V.; Spasic, M.V.; Kessler, R.; Stolte, J.; Hentze, M.W.; Muckenthaler, M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007, 109, 353-358.
8. Meynard, D.; Kautz, L.; Darnaud, V.; Canonne-Hergaux, F.; Coppin, H.; Roth, M.-P. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat. Genet. 2009, 41, 478-481.
9. Fillebeen, C.; Wilkinson, N.; Charlebois, E.; Katsarou, A.; Wagner, J.; Pantopoulos, K. Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling. Blood 2018, 132, 1829-1841.
10. Koch, P.-S.; Olsavszky, V.; Ulbrich, F.; Sticht, C.; Demory, A.; Leibing, T.; Henzler, T.; Meyer, M.; Zierow, J.; Schneider, S.; et al. Angiocrine Bmp2 signaling in murine liver controls normal iron homeostasis. Blood 2017, 129, 415-419.
11. Canali, S.; Wang, C.-Y.; Zumbrennen-Bullough, K.B.; Bayer, A.; Babitt, J.L. Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6. Am. J. Hematol. 2017, 92, 1204-1213.
12. Canali, S.; Zumbrennen-Bullough, K.B.; Core, A.B.; Wang, C.-Y.; Nairz, M.; Bouley, R.; Swirski, F.K.; Babitt, J.L. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 2017, 129, 405-414.
13. Armitage, A.E.; Eddowes, L.A.; Gileadi, U.; Cole, S.; Spottiswoode, N.; Selvakumar, T.A.; Ho, L.P.; Townsend, A.R.M.; Drakesmith, H. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011, 118, 4129-4139.
14. Camaschella, C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017, 31, 225-233.
15. Weiss, G.; Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011-1023.
16. Theurl, I.; Aigner, E.; Theurl, M.; Nairz, M.; Seifert, M.; Schroll, A.; Sonnweber, T.; Eberwein, L.; Witcher, D.R.; Murphy, A.T.; et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood 2009, 113, 5277-5286.
17. Stefanova, D.; Raychev, A.; Arezes, J.; Ruchala, P.; Gabayan, V.; Skurnik, M.; Dillon, B.J.; Horwitz, M.A.; Ganz, T.; Bulut, Y.; et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood 2017, 130, 245-257.
18. Michels, K.R.; Zhang, Z.; Bettina, A.M.; Cagnina, R.E.; Stefanova, D.; Burdick, M.D.; Vaulont, S.; Nemeth, E.; Ganz, T.; Mehrad, B. Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. JCI Insight 2017, 2, e92002.
19. Soares, M.P.; Weiss, G. The Iron age of host-microbe interactions. EMBO Rep. 2015, 16, 1482-1500.
20. Van Assche, G.; Dignass, A.; Bokemeyer, B.; Danese, S.; Gionchetti, P.; Moser, G.; Beaugerie, L.; Gomollón, F.; Häuser, W.; Herrlinger, K.; et al. European Crohn’s and Colitis Organisation Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. J. Crohns Colitis 2013, 7, 1-33.
21. Khan, A.N.; Hameed, A.; Naeem, M.; Murtaza, G.; Shah, N.A. Iron status and hemoglobin level in chronic renal insufficiency. Med. Forum Mon. 2008, 19, 11-15.
22. Macdougall, I.C.; Bircher, A.J.; Eckardt, K.-U.; Obrador, G.T.; Pollock, C.A.; Stenvinkel, P.; Swinkels, D.W.; Wanner, C.; Weiss, G.; Chertow, G.M.; et al. Iron management in chronic kidney disease: Conclusions from a " Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016, 89, 28-39.
23. Del Vecchio, L.; Locatelli, F. Anemia in chronic kidney disease patients: Treatment recommendations and emerging therapies. Expert Rev. Hematol. 2014, 7, 495-506.
24. Heath, J.; Weiss, J.; Lavau, C.; Wechsler, D. Iron Deprivation in Cancer--Potential Therapeutic Implications. Nutrients 2013, 5, 2836-2859.
25. Weiss, G.; Schett, G. Anaemia in inflammatory rheumatic diseases. Nat. Rev. Rheumatol. 2013, 9, 205-215.
26. Weiss, G.; Ganz, T.; Goodnough, L.T. Anemia of inflammation. Blood 2018.
27. Busti, F.; Marchi, G.; Ugolini, S.; Castagna, A.; Girelli, D. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals 2018, 11, 94.
28. Camaschella, C. Iron-Deficiency Anemia. N. Engl. J. Med. 2015, 373, 484-486.
29. Weiss, G.; Schaible, U.E. Macrophage defense mechanisms against intracellular bacteria. Immunol. Rev. 2015, 264, 182-203.
30. Recalcati, S.; Locati, M.; Gammella, E.; Invernizzi, P.; Cairo, G. Iron levels in polarized macrophages: Regulation of immunity and autoimmunity. Autoimmun. Rev. 2012, 11, 883-889.
31. Nairz, M.; Theurl, I.; Swirski, F.K.; Weiss, G. " Pumping iron”-How macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflügers Arch. Eur. J. Physiol. 2017, 469, 397-418.
32. Drakesmith, H.; Prentice, A.M. Hepcidin and the iron-infection axis. Science 2012, 338, 768-772.
33. Ludwiczek, S.; Aigner, E.; Theurl, I.; Weiss, G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101, 4148-4154.
34. Weiss, G.; Bogdan, C.; Hentze, M.W. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J. Immunol. 1997, 158, 420-425.
35. Pantopoulos, K.; Weiss, G.; Hentze, M.W. Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways. Mol. Cell. Biol. 1996, 16, 3781-3788.
36. Byrd, T.F.; Horwitz, M.A. Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma. J. Clin. Investig. 1993, 91, 969-976.
37. Mulero, V.; Brock, J.H. Regulation of iron metabolism in murine J774 macrophages: Role of nitric oxide-dependent and -independent pathways following activation with gamma interferon and lipopolysaccharide. Blood 1999, 94, 2383-2389.
38. Tilg, H.; Ulmer, H.; Kaser, A.; Weiss, G. Role of IL-10 for Induction of Anemia During Inflammation. J. Immunol. 2002, 169, 2204-2209.
39. Ganz, T.; Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 2015, 15, 500-510.
40. Nairz, M.; Schroll, A.; Haschka, D.; Dichtl, S.; Tymoszuk, P.; Demetz, E.; Moser, P.; Haas, H.; Fang, F.C.; Theurl, I.; et al. Genetic and Dietary Iron Overload Differentially Affect the Course of Salmonella Typhimurium Infection. Front. Cell. Infect. Microbiol. 2017, 7, 110.
41. Barber, M.F.; Elde, N.C. Escape from bacterial iron piracy through rapid evolution of transferrin. Science 2014, 346, 1362-1366.
42. Weiss, G.; Fuchs, D.; Hausen, A.; Reibnegger, G.; Werner, E.R.; Werner-Felmayer, G.; Wachter, H. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp. Hematol. 1992, 20, 605-610.
43. Weiss, G.; Werner-Felmayer, G.; Werner, E.R.; Grunewald, K.; Wachter, H.; Hentze, M.W. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J. Exp. Med. 1994, 180, 969-976.
44. Mencacci, A.; Cenci, E.; Boelaert, J.R.; Bucci, P.; Mosci, P.; Fè d’Ostiani, C.; Bistoni, F.; Romani, L. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J. Infect. Dis. 1997, 175, 1467-1476.
45. Oexle, H.; Kaser, A.; Möst, J.; Bellmann-Weiler, R.; Werner, E.R.; Werner-Felmayer, G.; Weiss, G. Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J. Leukoc. Biol. 2003, 74, 287-294.
46. Cherayil, B.J.; Ellenbogen, S.; Shanmugam, N.N. Iron and intestinal immunity. Curr. Opin. Gastroenterol. 2011, 27, 523-528.
47. Cassat, J.E.; Skaar, E.P. Iron in Infection and Immunity. Cell Host Microbe 2013, 13, 509-519.
48. Theurl, I.; Theurl, M.; Seifert, M.; Mair, S.; Nairz, M.; Rumpold, H.; Zoller, H.; Bellmann-Weiler, R.; Niederegger, H.; Talasz, H.; et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008, 111, 2392-2399.
49. Peyssonnaux, C.; Zinkernagel, A.S.; Datta, V.; Lauth, X.; Johnson, R.S.; Nizet, V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006, 107, 3727-3732.
50. Nairz, M.; Schleicher, U.; Schroll, A.; Sonnweber, T.; Theurl, I.; Ludwiczek, S.; Talasz, H.; Brandacher, G.; Moser, P.L.; Muckenthaler, M.U.; et al. Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection. J. Exp. Med. 2013, 210, 855-873.
51. Wu, A.; Tymoszuk, P.; Haschka, D.; Heeke, S.; Dichtl, S.; Petzer, V.; Seifert, M.; Hilbe, R.; Sopper, S.; Talasz, H.; et al. Salmonella Utilizes Zinc To Subvert Antimicrobial Host Defense of Macrophages via Modulation of NF-κ B Signaling. Infect. Immun. 2017, 85.
52. Paradkar, P.N.; De Domenico, I.; Durchfort, N.; Zohn, I.; Kaplan, J.; Ward, D.M. Iron depletion limits intracellular bacterial growth in macrophages. Blood 2008, 112, 866-874.
53. Ben-Othman, R.; Flannery, A.R.; Miguel, D.C.; Ward, D.M.; Kaplan, J.; Andrews, N.W. Leishmania-mediated inhibition of iron export promotes parasite replication in macrophages. PLoS Pathog. 2014, 10, e1003901.
54. Wu, Q.; Shen, Y.; Tao, Y.; Wei, J.; Wang, H.; An, P.; Zhang, Z.; Gao, H.; Zhou, T.; Wang, F.; et al. Hemojuvelin regulates the innate immune response to peritoneal bacterial infection in mice. Cell Discov. 2017, 3, 17028.
55. Neumann, W.; Hadley, R.C.; Nolan, E.M. Transition metals at the host-pathogen interface: How Neisseria exploit human metalloproteins for acquiring iron and zinc. Essays Biochem. 2017, 61, 211-223.
56. Weiss, G.; Carver, P.L. Role of divalent metals in infectious disease susceptibility and outcome. Clin. Microbiol. Infect. 2018, 24, 16-23.
57. Skaar, E.P.; Raffatellu, M. Metals in infectious diseases and nutritional immunity. Metallomics 2015, 7, 926-928.
58. Kim, A.; Fung, E.; Parikh, S.G.; Valore, E.V.; Gabayan, V.; Nemeth, E.; Ganz, T. A mouse model of anemia of inflammation: Complex pathogenesis with partial dependence on hepcidin. Blood 2014, 123, 1129-1136.
59. Nairz, M.; Ferring-Appel, D.; Casarrubea, D.; Sonnweber, T.; Viatte, L.; Schroll, A.; Haschka, D.; Fang, F.C.; Hentze, M.W.; Weiss, G.; et al. Iron Regulatory Proteins Mediate Host Resistance to Salmonella Infection. Cell Host Microbe 2015, 18, 254-261.
60. Guida, C.; Altamura, S.; Klein, F.A.; Galy, B.; Boutros, M.; Ulmer, A.J.; Hentze, M.W.; Muckenthaler, M.U. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 2015, 125, 2265-2275.
61. Moreira, A.C.; Neves, J.V.; Silva, T.; Oliveira, P.; Gomes, M.S.; Rodrigues, P.N. Hepcidin-(in)dependent mechanisms of iron metabolism regulation during infection by Listeria and Salmonella. Infect. Immun. 2017, 85, IAI-00353.
62. Mitterstiller, A.-M.; Haschka, D.; Dichtl, S.; Nairz, M.; Demetz, E.; Talasz, H.; Soares, M.P.; Einwallner, E.; Esterbauer, H.; Fang, F.C.; et al. Heme oxygenase 1 controls early innate immune response of macrophages to Salmonella Typhimurium infection. Cell. Microbiol. 2016, 18, 1374-1389.
63. Weis, S.; Carlos, A.R.; Moita, M.R.; Singh, S.; Blankenhaus, B.; Cardoso, S.; Larsen, R.; Rebelo, S.; Schäuble, S.; Del Barrio, L.; et al. Metabolic Adaptation Establishes Disease Tolerance to Sepsis. Cell 2017, 169, 1263.e14-1275.e14.
64. Gozzelino, R.; Jeney, V.; Soares, M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 323-354.
65. Portugal, S.; Carret, C.; Recker, M.; Armitage, A.E.; Gonçalves, L.A.; Epiphanio, S.; Sullivan, D.; Roy, C.; Newbold, C.I.; Drakesmith, H.; et al. Host-mediated regulation of superinfection in malaria. Nat. Med. 2011, 17, 732-737.
66. Stockman, R. The Treatment of Chlorosis by Iron and some Other Drugs. Br. Med. J. 1893, 1, 942-944.
67. Nairz, M.; Haschka, D.; Demetz, E.; Weiss, G. Iron at the interface of immunity and infection. Front. Pharmacol. 2014, 5, 152.
68. Weiss, G. Anemia of Chronic Disorders: New Diagnostic Tools and New Treatment Strategies. Semin. Hematol. 2015, 52, 313-320.
69. Nairz, M.; Theurl, I.; Wolf, D.; Weiss, G. Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation. Wien. Med. Wochenschr. 2016, 166, 411-423.
70. Torti, F.M.; Torti, S.V. Regulation of ferritin genes and protein. Blood 2002, 99, 3505-3516.
71. Garcia-Casal, M.N.; Peña-Rosas, J.P.; Pasricha, S.-R. Rethinking ferritin cutoffs for iron deficiency and overload. Lancet Haematol. 2014, 1, e92-e94.
72. Suchdev, P.S.; Namaste, S.M.; Aaron, G.J.; Raiten, D.J.; Brown, K.H.; Flores-Ayala, R. BRINDA Working Group Overview of the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) Project. Adv. Nutr. 2016, 7, 349-356.
73. Gale, E.; Torrance, J.; Bothwell, T. The quantitative estimation of total iron stores in human bone marrow. J. Clin. Investig. 1963, 42, 1076-1082.
74. Grote Beverborg, N.; Klip, I.T.; Meijers, W.C.; Voors, A.A.; Vegter, E.L.; van derWal, H.H.; Swinkels, D.W.; van Pelt, J.; Mulder, A.B.; Bulstra, S.K.; et al. Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circ. Heart Fail. 2018, 11, e004519.
75. Speeckaert, M.M.; Speeckaert, R.; Delanghe, J.R. Biological and clinical aspects of soluble transferrin receptor. Crit. Rev. Clin. Lab. Sci. 2010, 47, 213-228.
76. Brugnara, C.; Mohandas, N. Red cell indices in classification and treatment of anemias. Curr. Opin. Hematol. 2013, 20, 222-230.
77. Harms, K.; Kaiser, T. Beyond soluble transferrin receptor: Old challenges and new horizons. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29, 799-810.
78. Aguilar, R.; Moraleda, C.; Quintó, L.; Renom, M.; Mussacate, L.; Macete, E.; Aguilar, J.L.; Alonso, P.L.; Menéndez, C. Challenges in the Diagnosis of Iron Deficiency in Children Exposed to High Prevalence of Infections. PLoS ONE 2012, 7, e50584.
79. Castel, R.; Tax, M.G.H.M.; Droogendijk, J.; Leers, M.P.G.; Beukers, R.; Levin, M.-D.; Sonneveld, P.; Berendes, P.B. The transferrin/log(ferritin) ratio: A new tool for the diagnosis of iron deficiency anemia. Clin. Chem. Lab. Med. 2012, 50, 1343-1349.
80. Lasocki, S.; Baron, G.; Driss, F.; Westerman, M.; Puy, H.; Boutron, I.; Beaumont, C.; Montravers, P. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010, 36, 1044-1048.
81. Shu, T.; Jing, C.; Lv, Z.; Xie, Y.; Xu, J.; Wu, J. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: Pathogenic mechanisms and diagnosis. Eur. J. Haematol. 2015, 94, 67-73.
82. Bergamaschi, G.; Di Sabatino, A.; Albertini, R.; Costanzo, F.; Guerci, M.; Masotti, M.; Pasini, A.; Massari, A.; Campostrini, N.; Corbella, M.; et al. Serum Hepcidin in Inflammatory Bowel Diseases. Inflamm. Bowel Dis. 2013, 19, 2166-2172.
83. Van Santen, S.; van Dongen-Lases, E.C.; de Vegt, F.; Laarakkers, C.M.M.; van Riel, P.L.C.M.; van Ede, A.E.; Swinkels, D.W. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011, 63, 3672-3680.
84. Bregman, D.B.; Morris, D.; Koch, T.A.; He, A.; Goodnough, L.T. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol. 2013, 88, 97-101.
85. Steensma, D.P.; Sasu, B.J.; Sloan, J.A.; Tomita, D.K.; Loprinzi, C.L. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015, 125, 3669-3671.
86. Theurl, M.; Nairz, M.; Schroll, A.; Sonnweber, T.; Asshoff, M.; Haschka, D.; Seifert, M.; Willenbacher, W.; Wilflingseder, D.; Posch, W.; et al. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica 2014, 99, 1516-1524.
87. Takasawa, K.; Takaeda, C.; Maeda, T.; Ueda, N.; Takasawa, K.; Takaeda, C.; Maeda, T.; Ueda, N. Hepcidin-25, Mean Corpuscular Volume, and Ferritin as Predictors of Response to Oral Iron Supplementation in Hemodialysis Patients. Nutrients 2014, 7, 103-118.
88. Gaillard, C.A.; Bock, A.H.; Carrera, F.; Eckardt, K.-U.; Van Wyck, D.B.; Bansal, S.S.; Cronin, M.; Meier, Y.; Larroque, S.; Roger, S.D.; et al. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. PLoS ONE 2016, 11, e0157063.
89. Ford, B.A.; Eby, C.S.; Scott, M.G.; Coyne, D.W. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010, 78, 769-773.
90. Tessitore, N.; Girelli, D.; Campostrini, N.; Bedogna, V.; Pietro Solero, G.; Castagna, A.; Melilli, E.; Mantovani, W.; De Matteis, G.; Olivieri, O.; et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol. Dial. Transplant. 2010, 25, 3996-4002.
91. Kautz, L.; Jung, G.; Nemeth, E.; Ganz, T. Erythroferrone contributes to recovery from anemia of inflammation. Blood 2014, 124, 2569-2574.
92. Sonnweber, T.; Nachbaur, D.; Schroll, A.; Nairz, M.; Seifert, M.; Demetz, E.; Haschka, D.; Mitterstiller, A.M.; Kleinsasser, A.; Burtscher, M.; et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 2014, 63, 1951-1959.
93. Haase, V.H. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013, 27, 41-53.
94. Hanudel, M.R.; Rappaport, M.; Chua, K.; Gabayan, V.; Qiao, B.; Jung, G.; Salusky, I.B.; Ganz, T.; Nemeth, E. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 2018, 103, e141-e142.
95. Ganz, T.; Jung, G.; Naeim, A.; Ginzburg, Y.; Pakbaz, Z.; Walter, P.B.; Kautz, L.; Nemeth, E. Immunoassay for human serum erythroferrone. Blood 2017, 130, 1243-1246.
96. Mastrogiannaki, M.; Matak, P.; Mathieu, J.R.R.; Delga, S.; Mayeux, P.; Vaulont, S.; Peyssonnaux, C. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 2012, 97, 827-834.
97. Van der Vorm, L.N.; Hendriks, J.C.M.; Laarakkers, C.M.; Klaver, S.; Armitage, A.E.; Bamberg, A.; Geurts-Moespot, A.J.; Girelli, D.; Herkert, M.; Itkonen, O.; et al. Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material. Clin. Chem. 2016, 62, 993-1001.
98. Burisch, J.; Vegh, Z.; Katsanos, K.H.; Christodoulou, D.K.; Lazar, D.; Goldis, A.; O’Morain, C.; Fernandez, A.; Pereira, S.; Myers, S.; et al. Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study. J. Crohns Colitis 2017, 11, 1213-1222.
99. Ershler, W.B.; Chen, K.; Reyes, E.B.; Dubois, R. Economic Burden of Patients with Anemia in Selected Diseases. Value Heal. 2005, 8, 629-638.
100. Wouters, H.J.C.M.; van der Klauw, M.M.; de Witte, T.; Stauder, R.; Swinkels, D.W.; Wolffenbuttel, B.H.R.; Huls, G. Association of anemia with health-related quality of life and survival: A large population-based cohort study. Haematologica 2018.
101. Nishimoto, N.; Sasai, M.; Shima, Y.; Nakagawa, M.; Matsumoto, T.; Shirai, T.; Kishimoto, T.; Yoshizaki, K. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95, 56-61.
102. Yoshizaki, K.; Matsuda, T.; Nishimoto, N.; Kuritani, T.; Taeho, L.; Aozasa, K.; Nakahata, T.; Kawai, H.; Tagoh, H.; Komori, T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989, 74, 1360-1367.
103. Song, S.-N.J.; Tomosugi, N.; Kawabata, H.; Ishikawa, T.; Nishikawa, T.; Yoshizaki, K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010, 116, 3627-3634.
104. Kawabata, H.; Tomosugi, N.; Kanda, J.; Tanaka, Y.; Yoshizaki, K.; Uchiyama, T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica 2007, 92, 857-858.
105. Kurzrock, R.; Voorhees, P.M.; Casper, C.; Furman, R.R.; Fayad, L.; Lonial, S.; Borghaei, H.; Jagannath, S.; Sokol, L.; Usmani, S.Z.; et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or castleman disease. Clin. Cancer Res. 2013, 19, 3659-3670.
106. Casper, C.; Chaturvedi, S.; Munshi, N.; Wong, R.; Qi, M.; Schaffer, M.; Bandekar, R.; Hall, B.; van de Velde, H.; Vermeulen, J.; et al. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients with Multicentric Castleman Disease. Clin. Cancer Res. 2015, 21, 4294-4304.
107. Angevin, E.; Tabernero, J.; Elez, E.; Cohen, S.J.; Bahleda, R.; van Laethem, J.-L.; Ottensmeier, C.; Lopez-Martin, J.A.; Clive, S.; Joly, F.; et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2014, 20, 2192-2204.
108. Madeddu, C.; Gramignano, G.; Kotsonis, P.; Coghe, F.; Atzeni, V.; Scartozzi, M.; Macciò, A. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of Interleukin-6. Haematologica 2018.
109. Noguchi-Sasaki, M.; Sasaki, Y.; Shimonaka, Y.; Mori, K.; Fujimoto-Ouchi, K. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. BMC Cancer 2016, 16, 270.
110. Bergamaschi, G.; Di Sabatino, A.; Albertini, R.; Ardizzone, S.; Biancheri, P.; Bonetti, E.; Cassinotti, A.; Cazzola, P.; Markopoulos, K.; Massari, A.; et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor- treatment. Haematologica 2010, 95, 199-205.
111. Bes, C.; Yazici, A.; Soy, M. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis. Rheumatol. Int. 2013, 33, 1415-1418.
112. Davis, D.; Charles, P.J.; Potter, A.; Feldmann, M.; Maini, R.N.; Elliott, M.J. Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor alpha blockade. Br. J. Rheumatol. 1997, 36, 950-956.
113. Doyle, M.K.; Rahman, M.U.; Frederick, B.; Birbara, C.A.; de Vries, D.; Toedter, G.; Wu, X.; Chen, D.; Ranganath, V.K.; Westerman, M.E.; et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: Results of a phase 1, randomized, open-label trial. Rheumatology 2013, 52, 1214-1219.
114. Papadaki, H.A.; Kritikos, H.D.; Valatas, V.; Boumpas, D.T.; Eliopoulos, G.D. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: Improvement following anti-tumor necrosis factor-α antibody therapy. Blood 2002, 100, 474-482.
115. Cavallaro, F.; Duca, L.; Pisani, L.F.; Rigolini, R.; Spina, L.; Tontini, G.E.; Munizio, N.; Costa, E.; Cappellini, M.D.; Vecchi, M.; et al. Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Can. J. Gastroenterol. Hepatol. 2017, 2017, 1-12.
116. Song, S.-N.J.; Iwahashi, M.; Tomosugi, N.; Uno, K.; Yamana, J.; Yamana, S.; Isobe, T.; Ito, H.; Kawabata, H.; Yoshizaki, K. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res. Ther. 2013, 15, R141.
117. Koutroubakis, I.E.; Ramos-Rivers, C.; Regueiro, M.; Koutroumpakis, E.; Click, B.; Schwartz, M.; Swoger, J.; Baidoo, L.; Hashash, J.G.; Barrie, A.; et al. The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2015, 21, 1587-1593.
118. Pardanani, A.; Finke, C.; Abdelrahman, R.A.; Lasho, T.L.; Tefferi, A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am. J. Hematol. 2013, 88, 312-316.
119. Parganas, E.; Wang, D.; Stravopodis, D.; Topham, D.J.; Marine, J.C.; Teglund, S.; Vanin, E.F.; Bodner, S.; Colamonici, O.R.; van Deursen, J.M.; et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93, 385-395.
120. Pardanani, A.; Gotlib, J.R.; Jamieson, C.; Cortes, J.E.; Talpaz, M.; Stone, R.M.; Silverman, M.H.; Gilliland, D.G.; Shorr, J.; Tefferi, A. Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. J. Clin. Oncol. 2011, 29, 789-796.
121. Verstovsek, S.; Mesa, R.A.; Gotlib, J.; Levy, R.S.; Gupta, V.; DiPersio, J.F.; Catalano, J.V.; Deininger, M.; Miller, C.; Silver, R.T.; et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. N. Engl. J. Med. 2012, 366, 799-807.
122. Pardanani, A.; Laborde, R.R.; Lasho, T.L.; Finke, C.; Begna, K.; Al-Kali, A.; Hogan, W.J.; Litzow, M.R.; Leontovich, A.; Kowalski, M.; et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013, 27, 1322-1327.
123. Asshoff, M.; Petzer, V.; Warr, M.R.; Haschka, D.; Tymoszuk, P.; Demetz, E.; Seifert, M.; Posch, W.; Nairz, M.; Maciejewski, P.; et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 2017, 129, 1823-1830.
124. Cornez, I.; Yajnanarayana, S.P.; Wolf, A.M.; Wolf, D. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs. Mol. Cell. Endocrinol. 2017, 451, 88-96.
125. Nielsen, O.; Soendergaard, C.; Vikner, M.; Weiss, G. Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. Nutrients 2018, 10, 82.
126. Theurl, I.; Schroll, A.; Nairz, M.; Seifert, M.; Theurl, M.; Sonnweber, T.; Kulaksiz, H.; Weiss, G. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica 2011, 96, 1761-1769.
127. Lasocki, S.; Millot, S.; Andrieu, V.; Lettéron, P.; Pilard, N.; Muzeau, F.; Thibaudeau, O.; Montravers, P.; Beaumont, C. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Crit. Care Med. 2008, 36, 2388-2394.
128. Del Vecchio, L.; Locatelli, F. Clinical practice guidelines on iron therapy: A critical evaluation. Hemodial. Int. 2017, 21, S125-S131.
129. Drüeke, T.B.; Parfrey, P.S. Summary of the KDIGO guideline on anemia and comment: Reading between the (guide)line(s). Kidney Int. 2012, 82, 952-960.
130. Locatelli, F.; Bárány, P.; Covic, A.; De Francisco, A.; Del Vecchio, L.; Goldsmith, D.; Hörl, W.; London, G.; Vanholder, R.; Van Biesen, W.; et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol. Dial. Transplant. 2013, 28, 1346-1359.
131. The National Collaborating Centre for Chronic Conditions. Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children; Royal College of Physicians: London, UK, 2006; ISBN 9781860162930.
132. Kliger, A.S.; Foley, R.N.; Goldfarb, D.S.; Goldstein, S.L.; Johansen, K.; Singh, A.; Szczech, L. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am. J. Kidney Dis. 2013, 62, 849-859.
133. Singh, A.K.; Szczech, L.; Tang, K.L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D. CHOIR Investigators Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N. Engl. J. Med. 2006, 355, 2085-2098.
134. Drüeke, T.B.; Locatelli, F.; Clyne, N.; Eckardt, K.-U.; Macdougall, I.C.; Tsakiris, D.; Burger, H.-U.; Scherhag, A. CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006, 355, 2071-2084.
135. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.-U.; Gaillard, C.; Van Wyck, D.; Roubert, B.; Nolen, J.G.; Roger, S.D. FIND-CKD Study Investigators FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 2014, 29, 2075-2084.
136. Agarwal, R.; Kusek, J.W.; Pappas, M.K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015, 88, 905-914.
137. Gasche, C.; Lomer, M.C.E.; Cavill, I.; Weiss, G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004, 53, 1190-1197.
138. Nielsen, O.H.; Ainsworth, M.; Coskun, M.; Weiss, G. Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease. Medicine 2015, 94, e963.
139. Gasche, C.; Dejaco, C.; Reinisch, W.; Tillinger, W.; Waldhoer, T.; Fueger, G.F.; Lochs, H.; Gangl, A. Sequential Treatment of Anemia in Ulcerative Colitis with Intravenous Iron and Erythropoietin. Digestion 1999, 60, 262-267.
140. Dignass, A.U.; Gasche, C.; Bettenworth, D.; Birgegård, G.; Danese, S.; Gisbert, J.P.; Gomollon, F.; Iqbal, T.; Katsanos, K.; Koutroubakis, I.; et al. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. J. Crohns Colitis 2015, 9, 211-222.
141. Gisbert, J.P.; Bermejo, F.; Pajares, R.; Pérez-Calle, J.-L.; Rodríguez, M.; Algaba, A.; Mancenido, N.; de la Morena, F.; Carneros, J.A.; McNicholl, A.G.; et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm. Bowel Dis. 2009, 15, 1485-1491.
142. Reinisch, W.; Staun, M.; Tandon, R.K.; Altorjay, I.; Thillainayagam, A.V.; Gratzer, C.; Nijhawan, S.; Thomsen, L.L. A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1000 (Monofer) Compared with Oral Iron for Treatment of Anemia in IBD (PROCEED). Am. J. Gastroenterol. 2013, 108, 1877-1888.
143. Lee, T.; Clavel, T.; Smirnov, K.; Schmidt, A.; Lagkouvardos, I.; Walker, A.; Lucio, M.; Michalke, B.; Schmitt-Kopplin, P.; Fedorak, R.; et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017, 66, 863-871.
144. Onken, J.E.; Bregman, D.B.; Harrington, R.A.; Morris, D.; Acs, P.; Akright, B.; Barish, C.; Bhaskar, B.S.; Smith-Nguyen, G.N.; Butcher, A.; et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014, 54, 306-315.
145. Kulnigg, S.; Stoinov, S.; Simanenkov, V.; Dudar, L.V.; Karnafel, W.; Garcia, L.C.; Sambuelli, A.M.; D’Haens, G.; Gasche, C. A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled Trial. Am. J. Gastroenterol. 2008, 103, 1182-1192.
146. Lindgren, S.; Wikman, O.; Befrits, R.; Blom, H.; Eriksson, A.; Grännö, C.; Ung, K.-A.; Hjortswang, H.; Lindgren, A.; Unge, P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand. J. Gastroenterol. 2009, 44, 838-845.
147. Koutroubakis, I.E.; Ramos-Rivers, C.; Regueiro, M.; Koutroumpakis, E.; Click, B.; Schwartz, M.; Swoger, J.; Baidoo, L.; Hashash, J.G.; Barrie, A.; et al. Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort. J. Clin. Gastroenterol. 2016, 50, 638-643.
148. Iqbal, T.; Stein, J.; Sharma, N.; Kulnigg-Dabsch, S.; Vel, S.; Gasche, C. Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia. Dig. Dis. Sci. 2015, 60, 1375-1381.
149. Macdougall, I.C.; White, C.; Anker, S.D.; Bhandari, S.; Farrington, K.; Kalra, P.A.; McMurray, J.J.V.; Murray, H.; Steenkamp, R.; Tomson, C.R.V.; et al. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. Am. J. Nephrol. 2018, 48, 260-268.
150. Macdougall, I.C.; White, C.; Anker, S.D.; Bhandari, S.; Farrington, K.; Kalra, P.A.; McMurray, J.J.V.; Murray, H.; Tomson, C.R.V.; Wheeler, D.C.; et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N. Engl. J. Med. 2018.
151. Drakesmith, H.; Nemeth, E.; Ganz, T. Ironing out Ferroportin. Cell Metab. 2015, 22, 777-787.
152. Crielaard, B.J.; Lammers, T.; Rivella, S. Targeting iron metabolism in drug discovery and delivery. Nat. Rev. Drug Discov. 2017, 16, 400-423.
153. Sebastiani, G.; Wilkinson, N.; Pantopoulos, K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front. Pharmacol. 2016, 7, 160.
154. Means, R.T.; Krantz, S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J. Clin. Investig. 1993, 91, 416-419.
155. La Ferla, K.; Reimann, C.; Jelkmann, W.; Hellwig-Bürgel, T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J. 2002, 16, 1811-1813.
156. Cazzola, M.; Ponchio, L.; de Benedetti, F.; Ravelli, A.; Rosti, V.; Beguin, Y.; Invernizzi, R.; Barosi, G.; Martini, A. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87, 4824-4830.
157. Khalil, S.; Delehanty, L.; Grado, S.; Holy, M.; White, Z.; Freeman, K.; Kurita, R.; Nakamura, Y.; Bullock, G.; Goldfarb, A. Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J. Exp. Med. 2018, 215, 661-679.
158. Weiss, G.; Houston, T.; Kastner, S.; Jöhrer, K.; Grünewald, K.; Brock, J.H. Regulation of cellular iron metabolism by erythropoietin: Activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood 1997, 89, 680-687.
159. Cooke, K.S.; Hinkle, B.; Salimi-Moosavi, H.; Foltz, I.; King, C.; Rathanaswami, P.; Winters, A.; Steavenson, S.; Begley, C.G.; Molineux, G.; et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013, 122, 3054-3061.
160. Rothe, C.; Skerra, A. Anticalin® Proteins as Therapeutic Agents in Human Diseases. BioDrugs 2018, 32, 233-243.
161. Hohlbaum, A.M.; Gille, H.; Trentmann, S.; Kolodziejczyk, M.; Rattenstetter, B.; Laarakkers, C.M.; Katzmann, G.; Christian, H.J.; Andersen, N.; Allersdorfer, A.; et al. Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey. Br. J. Pharmacol. 2018, 175, 1054-1065.
162. Boyce, M.; Warrington, S.; Cortezi, B.; Zöllner, S.; Vauléon, S.; Swinkels, D.W.; Summo, L.; Schwoebel, F.; Riecke, K. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br. J. Pharmacol. 2016, 173, 1580-1588.
163. Macdougall, I.C.; Rumjon, A.; Cinco, J.; Goldstein, L.; Summo, L.; Vauleon, S.; Riecke, K. FP660 Pharmacokinetics and Pharmacodynamics of Lexaptepid, a Novel Anti-Hepcidin Molecule, in ESA-Resistant Haemodialysis Patients. Nephrol. Dial. Transplant. 2015, 30, iii294-iii295.
164. Georgiev, P.; Lazaroiu, M.; Ocroteala, L.; Grudeva-Popova, J.; Gheorghita, E.; Vasilica, M.; Popescu, S.M.; Cucuianu, A.; Summo, L.; Schwoebel, F.; et al. Abstract 3847: The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study. Cancer Res. 2014, 74, 3847.
165. Andriopoulos, B.; Corradini, E.; Xia, Y.; Faasse, S.A.; Chen, S.; Grgurevic, L.; Knutson, M.D.; Pietrangelo, A.; Vukicevic, S.; Lin, H.Y.; et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 2009, 41, 482-487.
166. Parrow, N.L.; Fleming, R.E. Bone Morphogenetic Proteins as Regulators of Iron Metabolism. Annu. Rev. Nutr. 2014, 34, 77-94.
167. Theurl, I.; Schroll, A.; Sonnweber, T.; Nairz, M.; Theurl, M.; Willenbacher, W.; Eller, K.; Wolf, D.; Seifert, M.; Sun, C.C.; et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011, 118, 4977-4984.
168. Babitt, J.L.; Huang, F.W.; Xia, Y.; Sidis, Y.; Andrews, N.C.; Lin, H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Investig. 2007, 117, 1933-1939.
169. Poli, M.; Asperti, M.; Ruzzenenti, P.; Mandelli, L.; Campostrini, N.; Martini, G.; Di Somma, M.; Maccarinelli, F.; Girelli, D.; Naggi, A.; et al. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochem. Pharmacol. 2014, 92, 467-475.
170. Petzer, V.; Tymoszuk, P.; Wake, M.; Bayliss, L.; Papworth, J.; Carvalho, J.; Deantonio, C.; Asshoff, M.F.; Seifert, M.; Berger, S.; et al. A Fully Human Anti-BMP6 Antibody Reduces the Need for Erythropoietin Stimulating Agent in Two Rodent Anemia of Chronic Disease Models. Blood 2018, 132, 1045.
171. Galli, M.; Chatterjee, M.; Grasso, M.; Specchia, G.; Magen, H.; Einsele, H.; Celeghini, I.; Barbieri, P.; Paoletti, D.; Pace, S.; et al. Phase I study of the heparanase inhibitor Roneparstat: An innovative approach for multiple myeloma therapy. Haematologica 2018.
172. Peterson, P.; Whatcott, C.; Siddiqui-Jain, A.; Weitman, S.; Kieran, M.; Bearss, D.J.; Warner, S.L. TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency. Blood 2017, 130, 937.
173. Kovac, S.; Böser, P.; Cui, Y.; Ferring-Appel, D.; Casarrubea, D.; Huang, L.; Fung, E.; Popp, A.; Mueller, B.K.; Hentze, M.W. Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels. Haematologica 2016, 101, e173-e176.
174. Barrington, P.; Sheetz, M.J.; Callies, S.; Waters, D.G.; Berg, P.H.; Pappas, D.; Marbury, T.C.; Decker, B.S.; Berg, J.K. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure. Blood 2016, 128, 1280.
175. Leung, D.; Hill, K.A.; De Rosa, D.C.; Xu, J.; Manetta, J.; Wroblewski, V.J.; Benschop, R.J. LY2928057, An Antibody Targeting Ferroportin, Is a Potent Inhibitor Of Hepcidin Activity and Increases Iron Mobilization In Normal Cynomolgus Monkeys. Blood 2013, 122, 3433.
176. Ashby, D.R.; Gale, D.P.; Busbridge, M.; Murphy, K.G.; Duncan, N.D.; Cairns, T.D.; Taube, D.H.; Bloom, S.R.; Tam, F.W.K.; Chapman, R.; et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010, 95, 505-508.
177. Kautz, L.; Jung, G.; Valore, E.V.; Rivella, S.; Nemeth, E.; Ganz, T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 2014, 46, 678-684.
178. Camaschella, C.; Pagani, A. Advances in understanding iron metabolism and its crosstalk with erythropoiesis. Br. J. Haematol. 2018, 182, 481-494.
179. Provenzano, R.; Besarab, A.; Wright, S.; Dua, S.; Zeig, S.; Nguyen, P.; Poole, L.; Saikali, K.G.; Saha, G.; Hemmerich, S.; et al. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Am. J. Kidney Dis. 2016, 67, 912-924.
180. Peyssonnaux, C.; Zinkernagel, A.S.; Schuepbach, R.A.; Rankin, E.; Vaulont, S.; Haase, V.H.; Nizet, V.; Johnson, R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Investig. 2007, 117, 1926-1932.
181. Cappellini, M.D.; Comin-Colet, J.; de Francisco, A.; Dignass, A.; Doehner, W.; Lam, C.S.; Macdougall, I.C.; Rogler, G.; Camaschella, C.; Kadir, R.; et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol. 2017, 92, 1068-1078.
182. Avni, T.; Leibovici, L.; Gafter-Gvili, A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: Systematic review and meta-analysis. Eur. J. Heart Fail. 2012, 14, 423-429.
183. Çekiç, C.; İpek, S.; Aslan, F.; Akpınar, Z.; Arabul, M.; Topal, F.; Sarıtaş Yüksel, E.; Alper, E.; Ünsal, B. The Effect of Intravenous Iron Treatment on Quality of Life in Inflammatory Bowel Disease Patients with Nonanemic Iron Deficiency. Gastroenterol. Res. Pract. 2015, 2015, 1-5.
184. Kovesdy, C.P.; Trivedi, B.K.; Kalantar-Zadeh, K.; Anderson, J.E. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006, 69, 560-564.
185. Okonko, D.O.; Mandal, A.K.J.; Missouris, C.G.; Poole-Wilson, P.A. Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol. 2011, 58, 1241-1251.
186. Enjuanes, C.; Bruguera, J.; Grau, M.; Cladellas, M.; Gonzalez, G.; Meroño, O.; Moliner-Borja, P.; Verdú, J.M.; Farré, N.; Comín-Colet, J. Iron Status in Chronic Heart Failure: Impact on Symptoms, Functional Class and Submaximal Exercise Capacity. Rev. Española Cardiol. 2016, 69, 247-255.
187. Anker, S.D.; Comin Colet, J.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N. Engl. J. Med. 2009, 361, 2436-2448.
188. Ponikowski, P.; van Veldhuisen, D.J.; Comin-Colet, J.; Ertl, G.; Komajda, M.; Mareev, V.; McDonagh, T.; Parkhomenko, A.; Tavazzi, L.; Levesque, V.; et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 2015, 36, 657-668.
189. Stauder, R.; Valent, P.; Theurl, I. Anemia at older age: Etiologies, clinical implications, and management. Blood 2018, 131, 505-514.
190. Mabeza, G.F.; Loyevsky, M.; Gordeuk, V.R.; Weiss, G. Iron chelation therapy for malaria: A review. Pharmacol. Ther. 1999, 81, 53-75.
191. Zlotkin, S.; Newton, S.; Aimone, A.M.; Azindow, I.; Amenga-Etego, S.; Tchum, K.; Mahama, E.; Thorpe, K.E.; Owusu-Agyei, S. Effect of Iron Fortification on Malaria Incidence in Infants and Young Children in Ghana. JAMA 2013, 310, 938-947.
192. Zhang, D.-L.; Wu, J.; Shah, B.N.; Greutélaers, K.C.; Ghosh, M.C.; Ollivierre, H.; Su, X.-Z.; Thuma, P.E.; Bedu-Addo, G.; Mockenhaupt, F.P.; et al. Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. Science 2018, 359, 1520-1523.
193. Sazawal, S.; Black, R.E.; Ramsan, M.; Chwaya, H.M.; Stoltzfus, R.J.; Dutta, A.; Dhingra, U.; Kabole, I.; Deb, S.; Othman, M.K.; et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet 2006, 367, 133-143.
194. Soofi, S.; Cousens, S.; Iqbal, S.P.; Akhund, T.; Khan, J.; Ahmed, I.; Zaidi, A.K.; Bhutta, Z.A. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: A cluster-randomised trial. Lancet 2013, 382, 29-40.
195. Kortman, G.A.M.; Reijnders, D.; Swinkels, D.W. Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD. Hemodial. Int. 2017, 21, S28-S36.
196. Paganini, D.; Uyoga, M.; Zimmermann, M. Iron Fortification of Foods for Infants and Children in Low-Income Countries: Effects on the Gut Microbiome, Gut Inflammation, and Diarrhea. Nutrients 2016, 8, 494.
197. Moschen, A.R.; Gerner, R.R.; Wang, J.; Klepsch, V.; Adolph, T.E.; Reider, S.J.; Hackl, H.; Pfister, A.; Schilling, J.; Moser, P.L.; et al. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe 2016, 19, 455-469.
198. Scheers, N.M.; Pereira, D.I.A.; Faria, N.; Powell, J.J. Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells. Oncotarget 2018, 9, 17066-17077.
199. Porto, G.; De Sousa, M. Iron overload and immunity. World J. Gastroenterol. 2007, 13, 4707-4715.
200. Hara, N.; Okamoto, N.; Imanishi, K.; Takahashi, T.; Makiyama, K. Improvement in reliability of InP-based HEMTs by suppressing impact ionization. Electron. Commun. Jpn. Part II Electron. 2007, 90, 33-38.
201. Weiss, G.; Meusburger, E.; Radacher, G.; Garimorth, K.; Neyer, U.; Mayer, G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003, 64, 572-578.
202. Ibrahim, A.S.; Gebermariam, T.; Fu, Y.; Lin, L.; Husseiny, M.I.; French, S.W.; Schwartz, J.; Skory, C.D.; Edwards, J.E.; Spellberg, B.J. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Investig. 2007, 117, 2649-2657.
203. Jankowska, E.A.; Rozentryt, P.; Witkowska, A.; Nowak, J.; Hartmann, O.; Ponikowska, B.; Borodulin-Nadzieja, L.; Banasiak, W.; Polonski, L.; Filippatos, G.; et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur. Heart J. 2010, 31, 1872-1880.
204. Macdougall, I.C.; Canaud, B.; De Francisco, A.L.M.; Filippatos, G.; Ponikowski, P.; Silverberg, D.; Van Veldhuisen, D.J.; Anker, S.D. Beyond the cardiorenal anaemia syndrome: Recognizing the role of iron deficiency. Eur. J. Heart Fail. 2012, 14, 882-886.